The Food and Drug Administration (FDA) has approved the immunotherapy drug atezolizumab in combination with chemotherapy for ...

Researchers have unveiled a breakthrough showing that a subset of colorectal tumors can be eliminated using immunotherapy alone, without chemotherapy or surgery. The finding signals a potential shift ...

The Food and Drug Administration (FDA) approved Tecentriq (atezolizumab) in combination with chemotherapy on Oct. 8 as an ...

A pattern-based p53 immunohistochemistry test identified patients with colorectal liver metastases at nearly four times the ...

Ficerafusp Alfa (BCA101) With Pembrolizumab for Recurrent or Metastatic Head and Neck Squamous Cell Carcinoma: Two-Year Results of an Expansion Cohort of a Phase I/Ib Trial Participants received a ...

Akeso, Inc. (9926.HK) ("Akeso" or the "Company") announced that the first patient has been dosed in a Phase III clinical study (COMPASSION-40/AK104-313) evaluating cadonilimab, its first-in-class PD-1 ...

Colorectal cancer most often spreads to the liver. When those liver tumors (called liver metastases) can be removed with ...

A meta-analysis of 41 studies and 3,058 patients shows that detectable circulating tumor DNA after neoadjuvant therapy ...

Early-onset colorectal cancer with liver-only metastases can have significant differences in biology from late-onset malignancies.A study of nearly 1,700 individuals from Australia showed early-onset ...